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Abstract
Purpose of review—It is well established that blocking renin-angiotensin II-aldosterone system 
(RAAS) is effective for the treatment of cardiovascular and renal complications in hypertension 
and diabetes mellitus. Although the induction of transforming growth factor beta1 (TGFbeta1) by 
components of RAAS mediates the hypertrophic and fibrogenic changes in cardiovascular-renal 
complications, it is still controversial as to whether TGFbeta1 can be a target to prevent such 
complications. Here we review recent findings on the role of TGFbeta1 in fluid homeostasis, 
focusing on the relationship with aldosterone.
Recent findings—TGFbeta1 suppresses adrenal production of aldosterone and renal tubular 
sodium reabsorption. We have generated mice with TGFbeta1 mRNA expression graded in five 
steps from 10% to 300% normal, and found that blood pressure and plasma volume are negatively 
regulated by TGFbeta1. Notably, the 10 % hypomorph exhibits primary aldosteronism and sodium 
and water retention due to markedly impaired urinary excretion of water and electrolytes.
Summary—These results identify TGFbeta signaling as an important counterregulatory system 
against aldosterone. Understanding the molecular mechanisms for the suppressive effects of 
TGFbeta1 on adrenocortical and renal function may further our understanding of primary 
aldosteronism as well as assist in the development of novel therapeutic strategies for hypertension.
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Introduction
Renin-angiotensin-aldosterone system (RAAS) functions as an endocrine and autocrine/
paracrine system to play an integral role in cardiovascular and renal physiology by 
regulating blood pressure, fluid volume, and electrolyte balance[1,2] as well as the 
development of fibrosis and remodeling in heart and kidney tissue. Its excessive activation is 
associated with the induction and progression of hypertension, atherosclerosis, cardiac 
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hypertrophy, heart failure, cardiovascular events including myocardial infarction and stroke, 
and chronic kidney disease. Therefore, blocking RAAS provides beneficial effects for the 
treatment of cardiovascular and renal disease. Experimental and clinical evidence indicates 
that pharmacological inhibition of RAAS with angiotensin-converting enzyme inhibitors, 
angiotensin II type 1 receptor blockers, and mineralocorticoid receptor antagonists is 
effective in treating hypertension, heart failure, and chronic kidney diseases, including 
diabetic renal injury. The results show a reduction in morbidity and mortality by 
cardiovascular diseases worldwide. However, many patients are unable to benefit from these 
therapies to due contraindications from taking RAAS modulators such as allergic reactions 
or severely diminished renal function. Therefore, novel therapeutic agents that could bypass 
these contraindications would be clinically important.
Transforming growth factor beta1 (TGFbeta1), the prototypic member of the TGFbeta 
superfamily, is a potent pleiotropic cytokine with effects on a broad range of biological 
processes including apoptosis[3], cell proliferation[4], tumor suppression[4], senescence[5], 
differentiation[6], migration[7], immunity[8], osteogenesis[9], adipogenesis[10], and wound 
healing[11]. In addition, a growing number of convincing evidence indicates that both 
angiotensin II and aldosterone activate TGFbeta signaling, which mediates many of the 
complications of RAAS-related hypertension including progressive renal dysfunction[2] and 
cardiac hypertrophy[12]. As such, development of therapeutic strategies targeting TGFbeta 
signaling may be a way to effectively treat hypertension, heart failure, and chronic kidney 
disease in patients who cannot tolerate RAAS modulators.
However, whether TGFbeta1 plays a role in the control of blood pressure and/or of RAAS 
has not yet been clearly demonstrated. In humans, the 915C allele of a single nucleotide 
polymorphism in the TGFbeta1 gene (TGFB1), which leads to proline at residue 25 within 
the signal peptide sequence, has been associated in a population with a reduced risk of 
hypertension[13]. The 869C allele of a second polymorphism, which leads to proline at 
residue 10 within the signal peptide sequence, has been associated in a population with an 
increased risk of hypertension[14,15], but how the changes in the functional effects of 
TGFbeta1 affect blood pressure remains undetermined. Since they are polymorphisms in the 
coding region which presumably result in functional changes of the protein, it remains 
unclear whether they cause loss-of-function or gain-of-function.
Recently, a set of C57BL/6 mice having 5 different Tgfb1 mRNA expression of ~10%, 50%, 
200%, and 300% normal levels have been generated, and it has been found that blood 
pressure is negatively regulated by TGFbeta1[16]. It is noteworthy that the mice with 10% 
normal TGFbeta1 expression develop hypertension, primary aldosteronism and markedly 
impaired diuresis and natriuresis without developing renal excretory dysfunction.
These in vivo findings, together with previous ex vivo and in vitro findings that TGFbeta1 
suppresses the adrenocortical synthesis of mineralocorticoids and their activation of renal 
tubular sodium reabsorption, suggest that TGFbeta1 plays a critical physiological role in 
controlling blood pressure and maintaining fluid homeostasis. In the present review, we will 
focus on the relationship between TGFbeta1 and aldosterone in RAAS in the 
pathophysiology of hypertension.
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Activation of the TGFbeta signaling by aldosterone
Previous studies have demonstrated that most components of the renin-angiotensin-
aldosterone system (RAAS) can up-regulate TGFbeta signaling independently of blood 
pressure. For example, renin via the (pro)renin receptor[17–19], angiotensin II via the AT1 
receptor[20–22], and aldosterone via the mineralocorticoid receptor[23–25] all increase 
TGF-beta1 expression, and angiotensin II also stimulates expression of TGF-beta receptors 
leading to a further amplification of the effects by TGF-beta1[2].
TGFbeta1 mRNA expression was increased in cultured HL-1 cardiomyocytes receiving 
aldosterone[26], and in cultured renal fibroblast cells exposed to aldosterone[27]. In mice 
treated with a NOS inhibitor NG-nitro-L-arginine methyl ester (L-NAME) and angiotensin 
II, genetic deficiency of the mineralocorticoid receptor in myeloid cells significantly 
attenuated inflammation, fibrosis and the mRNA levels of TGFbeta1 is the heart and 
aorta[28]. Aldosterone also increased the secretion of TGFbeta1 in dendritic cells[29].
However, the mechanism(s) whereby aldosterone increases TGFbeta1 expression is not fully 
understood. Han et al. have reported that the stimulation of TGFbeta1 mRNA expression by 
aldosterone is significantly inhibited by an extracellular-signal regulated kinase 1/2 inhibitor 
PD98059, a c-Jun N-terminal kinase inhibitor SP600125, or an activator protein-1 inhibitor 
curcumin in rat mesangial cells[30]. On the other hand, Juknevicius et al. have shown that 
aldosterone provokes urinary excretion of TGF-beta1 without influencing renal TGFbeta1 
transcripts, suggesting posttranscriptional enhancement of renal TGFbeta1[31].
Increased renal production of TGFbeta1 is associated with various diseases related to the 
activation of RAAS such as hypertension and diabetes mellitus. Additionally, urinary 
TGFbeta1 has been found to be associated with increasing interstitial fibrosis as well as 
proteinuria and mesangial expansion in patients with certain glomerulonephritides[32]. 
Urinary TGFbeta1 excretion reflects renal TGFbeta1 production. As such, urinary TGFbeta1 
excretion is a useful marker to assess the efficacy of treatment with RAAS inhibitors in 
clinical settings. For example, losartan, an angiotensin II type 1 receptor blocker, and 
spironolactone, a mineralocorticoid receptor antagonist, were reported to reduce urinary 
TGFbeta1 excretion[33,34].
These data indicate that TGFbeta signaling is intimately associated with chronic kidney 
disease. Additionally, it is closely tied into the RAAS, which leads to cardiorenal 
complications. TGFbeta signaling is known to play an integral role in fibrosis, and these data 
demonstrate that TGFbeta1 plays a pivotal role in the development of cardiorenal 
complications due to its interplay with the RAAS.
TGFbeta1 negatively regulates aldosterone synthesis
In contrast to the stimulatory effect of aldosterone on the expression of TGFbeta1, TGFbeta1 
has been shown to exert potent inhibitory effects on aldosterone synthesis in cultured 
adrenocortical cells[35–37].
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Hotta et al. have shown that TGFbeta1 inhibits the formation of the delta 4-steroids 
including cortisol, corticosterone, aldosterone, and androstenedione in cultured bovine 
adrenocortical cells[35]. TGFbeta1 significantly decreased the activity of cholesterol side-
chain cleavage, which is the first enzymatic step of steroidogenesis, and reduced the protein 
levels for cytochrome P450 side-chain cleavage (P450scc), adrenodoxin and adrenodoxin 
reductase in cultured sheep adrenal cells[38]. TGFbeta1 also decreases the transcript levels 
of steroidogenic acute regulatory protein (StAR), which assists transport of cholesterol from 
the outer mitochondrial membrane to the inner membrane where P450scc resides, in bovine 
adrenocortical cells[39]. Le Roy et al. reported that TGFbeta1 reduced adrenocorticotropin-
induced cortisol production and decreased the transcript levels of steroid 17-alpha-
monooxygenase (Cyp17a1), hydroxyl-delta-5-steroid dehydrogenase, 3 beta- and steroid 
delta-isomerase 1 (Hsd3b1), and StAR in the bovine adrenocortical cells[40]. These results 
demonstrate that TGFbeta1 suppresses multiple enzymatic steps of steroidogenesis that are 
upstream of the aldosterone synthesis in the adrenal cortex.
Recently, Liakos et al. have reported that TGFbeta1 reduced forskolin-induced production of 
cortisol and 11-hydroxyandrostenedione by 85% and angiotensin II-induced aldosterone 
production by 80%. TGFbeta1 strongly inhibits forskolin-induced steroid 11beta-
hydroxylase (Cyp11b1) activity and Cyp11b1 mRNA levels, as well as angiotensin II-
induced aldosterone synthase (Cyp11b2) activity and Cyp11b2 mRNA levels in the human 
adrenocortical tumor cell line NCI-H295R[36]. The promoter activity of Cyp11b1 studied 
with the luciferase assay was suppressed by TGFbeta1, but the responsible site was different 
from Smads-binding sequences, suggesting that the repression of promoter activity of 
Cyp11b1 by TGFbeta1 is indirect[36]. Indeed, TGFbeta1 inhibits transcription of 
steroidogenic factor 1[41], which plays an important role in the development of adrenal and 
gonadal steroidogenic cells[42] and enhances transcription of steroidogenic enzymes 
including Cyp11a1, steroid 21-hydroxylase (Cyp21a1), Cyp11b1 and Cyp11b2[43] by 
binding a shared promoter element[44].
These findings in cultured adrenocortical cells have been reproduced in mice having 
TGFbeta1 mRNA expression graded in five steps from 10% normal to 300% normal[3]. 
Higher than normal levels of TGFbeta1 lead to reduced plasma aldosterone levels despite the 
plasma volume being decreased, due to reduced expression of Cyp11b1, Cyp11b2, Hsd3b1, 
and Star, whereas lower than normal levels of TGFbeta1 lead to increased plasma 
aldosterone levels despite the plasma volume being expanded, due to increased expression of 
these genes.
In addition to the alteration in plasma aldosterone levels, corticosterone levels were also 
significantly higher than normal in TGFbeta1 hypomorphic mice, whereas in hypermorphic 
mice plasma aldosterone levels were significantly lower than normal[16]. The plasma active 
renin and angiotensin II levels were lower than normal in hypomorphic mice and higher than 
normal in hypermorphic mice. Additionally, the hypomorphic mice had a markedly higher 
systolic blood pressure and less natriuresis than WT mice, which was normalized by 
administration of spironolactone, a mineralocorticoid receptor antagonist, or amiloride, an 
epithelial sodium channel (ENaC) blocker. This suggests that TGFbeta signaling plays an 
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important role in regulating fluid homeostasis at least partly via suppression of 
corticosteroid synthesis and ENaC activity[16].
Microscopic examination of the adrenals showed no structural abnormalities, such as 
nodular hyperplasia, in any of the mice, but the adrenal weight normalized to body weight 
was doubled in the hypomorphic mice. Therefore, the hypomorphic mice can reasonably be 
classified as having secondary hypertension due to primary aldosteronism comparable to that 
seen in humans with idiopathic bilateral adrenal hyperplasia.
TGFbeta1 regulates adrenal development and can induce apoptosis in human adrenocortical 
H295R cells[45]. Interestingly, TGFbeta signaling pathway may be associated with 
development of adrenocortical tumors in human[46]. The expression of SMAD3 that is one 
of the components of TGFbeta signaling was low in malignant adrenocortical carcinomas.
Although molecular targets of TGFbeta1 in adrenocortical cells may differ between species 
and further investigation is needed, evidence has shown that TGFbeta1 regulates adrenal 
development and inhibits steroidogenesis in adrenal cortex. Furthermore, recent reports 
suggest interactions between TGFbeta signaling and adrenocortical tumorigenesis.
TGFbeta1 and aldosterone differentially regulate renal sodium reabsorption
In addition to the suppressive effect of TGFbeta1 on adrenocortical function, TGFbeta1 also 
directly inhibits ENaC activity stimulated by aldosterone in the kidney. Aldosterone exerts 
its pressor effect via expanding extracellular fluid volume through stimulating the activity of 
ENaC, which is located in the “aldosterone-sensitive distal nephron” including late distal 
convoluted tubules 2, connecting tubules, and collecting ducts in the kidney[47,48]. In the 
collecting duct, principal cells contain the machinery to respond to aldosterone and to absorb 
Na+. Three molecular complexes are necessary for this aldosterone response: 
mineralocorticoid receptors, ENaC, and Na+/K+-ATPase. All of these 3 components are 
present along the aldosterone-sensitive distal nephron. The activity of ENaC is positively 
regulated by plasma aldosterone levels and correlates with dietary sodium intake. The effect 
of aldosterone on Na+ transport appears to be greater on ENaC than on the Na+/K+-ATPase. 
Interestingly, the effect of aldosterone on the ENaC activity is rapid (< 2 min) and mediated 
by plasma membrane steroid receptors, which is not inhibited by cycloheximide, an inhibitor 
of protein synthesis, suggesting the presence of non-genomic mechanisms[49,50] (Figure).
Although regulation of ENaC by aldosterone is extremely important to Na+ homeostasis and 
blood pressure control, variety of other hormones including TGFbeta1 regulate ENaC 
activity either in parallel with aldosterone or independently[48]. Husted et al. reported that 
TGFbeta1 inhibits the increase of Na+ entry across the apical membrane in the rat inner 
medullary collecting duct cells due to mineralocorticoid activity [50,51]. Peters et al. 
reported that TGFbeta1 promotes internalization of betaENaC and destabilizes the whole 
ENaC complex in the epithelial cell surface[52]. We also reported that the open probability, 
functional expression and total activity of ENaC in the collecting duct cell microdissected 
from TGFbeta1 hypomorphic mice are significantly greater than those from WT mice[16]. 
In addition, collecting duct specific overexpression of TGFbeta1 partly restores natriuresis in 
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mice with low Tgfb1 expression (unpublished observation). These findings indicate that 
TGFbeta1 prevents Na+ absorption via ENaC even when the channel is fully activated by 
aldosterone.
Recently, protease nexin-1 (PN-1) was identified as an endogeneous inhibitor for prostasin 
which has been shown to increase ENaC activity[53]. PN-1 belongs to the serpin (serine 
protease inhibitor) family and is known to be an endogeneous inhibitor for alpha-thrombin, 
plasmin, and plasminogen activators. PN-1 inhibited prostasin-induced ENaC activation in 
Xenopus oocytes, and knock down of PN-1 gene expression increased baseline sodium 
current in M-1 cells; a mouse cortical collecting duct cell line[54]. Moreover, prostasin and 
PN-1 appear to be reciprocally regulated by aldosterone (increased prostasin and decreased 
PN-1) and TGFbeta1 (decreased prostasin and increased PN-1) [54]. TGFbeta1-induced 
PN-1 overexpression is associated with an increase in Smad2 binding to the promoter of 
PN-1 in human vascular smooth muscle cells[55]. In another study, TGFbeta1 inhibited the 
transepithelial electrical current, which is mainly amiloride sensitive and relies on the 
alphaENaC expression, in mpkCCDcl4 cells; a mouse cortical collecting duct cell line[56]. 
Removal of the N-terminus of Smad4 not only abolished the inhibitory effects of Smad4 on 
sodium current but also prevented the inhibition of sodium current by TGFbeta1. It suggests 
that TGFbeta1 decreases the ENaC functionality via a Smad4-dependent pathway.
It has been demonstrated that TGFbeta1 and aldosterone differentially regulate renal sodium 
reabsorption in proximal tubules as well. Human, rat, and mouse proximal tubular cells 
express mineralocorticoid receptors and Na+/K+-ATPase alpha1 subunits[57]. In human 
kidney proximal tubule HKC11 cells, aldosterone increases Na+/K+-ATPase-mediated 86Rb 
uptake[57]. In primary human proximal tubule epithelial cells, aldosterone stimulates Na+/
H+ exchange activity with an increase in cell surface expression of Na+/H+ exchanger 3[58]. 
In contrast, TGFbeta1 induces dose dependent decrease in the activity of Na+/K+-
ATPase[59] and the expression of alpha and beta subunits of Na+/K+-ATPase in rabbit 
primary proximal tubule cells[60].
The precise molecular mechanism by which TGFbeta1 reduces the renal actions of 
aldosterone is still poorly understood. However, it’s probably multifactorial and likely 
involves differential metabolic effects of aldosterone and TGFbeta1 on mitochondrial 
oxidative phosphorylation[59].
Conclusion
It is well established that blocking RAAS provides beneficial effects for the treatment of 
cardiovascular and renal complications in hypertension and diabetes. Although the induction 
of TGFbeta1 by angiotensin II and aldosterone mediates the fibrogenic changes in these 
complications, TGFbeta1 inhibition alone is unlikely to be a successful target to inhibit the 
fibrogenic complications in renal and cardiac disease due to its role in salt retention and 
hypertension. More research is needed to further tease out the molecular mechanisms 
between TGFbeta1 and adrenocortical function, and this might lead to enhanced 
understanding about the pathophysiology of primary aldosteronism and allow for new 
therapeutic strategies for patients with hypertension.
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• Recent evidence demonstrates that TGFbeta1 has an inhibitory role in adrenal 
production of corticosteroids including aldosterone.
• TGFbeta1 antagonizes renal tubular reabsorption of sodium by aldosterone via 
inhibiting the activity of ENaC and Na+/K+-ATPase.
• Phenotype of the TGFbeta1 hypomorphic mice indicates that TGFbeta1 is 
physiologically important for normal natriuresis and protects against the 
development of primary aldosteronism.
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A diagram depicting the effects of transforming growth factor-beta1 (TGF-1) on the adrenal 
production of corticosteroids and on the natriferic function in collecting duct principal cells. 
PN-1, protease nexin-1; MR, mineralocorticoid receptor; ENaC, epithelial sodium channel.
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